PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company's national service platform, VIP Petcare, operates in over 3,400 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care.

Company profile
Ticker
PETQ
Exchange
Website
CEO
McCord Christensen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ECP IV TS Investor Co. • PetIQ Holdings, LLC • PetIQ, LLC • TruRX, LLC • Tru Prodigy, LLC • M&C USA, LLC • Mark and Chappell Limited • Mark and Chappell (Ireland) Limited • Prodex D.O.O. • PetIQ MFG, LLC ...
PETQ stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
28 Feb 23
8-K
PetIQ, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 23
8-K/A
Entry into a Material Definitive Agreement
10 Feb 23
8-K
Entry into a Material Definitive Agreement
9 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
PetIQ, Inc. Reports Third Quarter 2022 Financial Results
9 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
31 Oct 22
UPLOAD
Letter from SEC
25 Oct 22
CORRESP
Correspondence with SEC
19 Oct 22
CORRESP
Correspondence with SEC
14 Oct 22
Transcripts
PETQ
Earnings call transcript
2022 Q4
28 Feb 23
PETQ
Earnings call transcript
2022 Q3
10 Nov 22
PETQ
Earnings call transcript
2022 Q2
13 Aug 22
PETQ
Earnings call transcript
2022 Q1
5 May 22
PETQ
Earnings call transcript
2021 Q4
2 Mar 22
PETQ
Earnings call transcript
2021 Q3
4 Nov 21
PETQ
Earnings call transcript
2021 Q2
5 Aug 21
PETQ
Earnings call transcript
2021 Q1
9 May 21
PETQ
Earnings call transcript
2020 Q4
27 Feb 21
PETQ
Earnings call transcript
2020 Q3
8 Nov 20
Latest ownership filings
4
Michael A Smith
14 Mar 23
4
McCord Christensen
14 Mar 23
4
Robert Michael Herrman
14 Mar 23
4
McCord Christensen
3 Mar 23
4
Michael A Smith
3 Mar 23
4
Robert Michael Herrman
3 Mar 23
4
Zvi Glasman
3 Mar 23
4
Robert Michael Herrman
28 Feb 23
4
Michael A Smith
28 Feb 23
4
McCord Christensen
28 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 101.27 mm | 101.27 mm | 101.27 mm | 101.27 mm | 101.27 mm | 101.27 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.01 mm | 2.93 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 5.67 mm | 8.26 mm | n/a | n/a |
Cash remaining | n/a | n/a | 95.59 mm | 93.01 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 47.5 | 31.7 | n/a | n/a |
Institutional ownership, Q4 2022
30.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 152 |
Opened positions | 33 |
Closed positions | 23 |
Increased positions | 50 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 234.02 bn |
Total shares | 31.53 mm |
Total puts | 118.80 k |
Total calls | 95.70 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Eos Management | 1.97 mm | $18.19 bn |
Ecp Helios Partners Iv | 1.97 mm | $0.00 |
BLK Blackrock | 1.82 mm | $16.82 bn |
Applied Fundamental Research | 1.63 mm | $15.08 bn |
Vanguard | 1.59 mm | $14.66 bn |
Boston Partners | 1.56 mm | $14.97 bn |
Alger Associates | 1.23 mm | $31.83 mm |
Aristotle Capital Boston | 1.18 mm | $10.84 bn |
GS Goldman Sachs | 977.66 k | $9.01 bn |
Nepsis | 885.20 k | $8.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 23 | Herrman Robert Michael | Class A Common Stock | Payment of exercise | Dispose F | No | No | 10.96 | 206 | 2.26 k | 14,764 |
13 Mar 23 | Herrman Robert Michael | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 677 | 0.00 | 14,970 |
13 Mar 23 | Herrman Robert Michael | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 677 | 0.00 | 0 |
13 Mar 23 | Christensen McCord | Class A Common Stock | Payment of exercise | Dispose F | No | No | 10.96 | 616 | 6.75 k | 93,105 |
13 Mar 23 | Christensen McCord | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 2,029 | 0.00 | 93,721 |
13 Mar 23 | Christensen McCord | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 2,029 | 0.00 | 0 |
12 Mar 23 | Herrman Robert Michael | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.13 | 557 | 6.20 k | 14,293 |
12 Mar 23 | Herrman Robert Michael | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,834 | 0.00 | 14,850 |
12 Mar 23 | Herrman Robert Michael | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 1,834 | 0.00 | 1,835 |
12 Mar 23 | Christensen McCord | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.13 | 1,724 | 19.19 k | 91,692 |
News
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
1 Mar 23
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
1 Mar 23
Earnings Scheduled For February 28, 2023
28 Feb 23
Earnings Preview For PetIQ
27 Feb 23
Benchmark Reiterates Buy on PetIQ, Maintains $30 Price Target
13 Feb 23